GSK

Stock splits

$GSK chatter on StockTwits

• 
  The mann@clan12h

  $JNJ $ABBV $GSK If you know Dry Powder Inhalation (DPI), you know it's great for all Mannkind. 🚫💉

  View on StockTwits ↗
• 
  Tony M@SellasgpsCurativeBAT11Bullish19h

  $RVMD $SLS $GSK $NUVL Buy out can happens anytime given the overwhelming success? Ex: GSK closed the Nuvalent, Inc. acquisition on 15th July. Jideytro had FDA approval days later. That timing isn't a credit to fast integration; it's a feature of how these deals actually work that doesn't get discussed enough: the regulatory clock doesn't reset on a change of ownership. The ARROS-1 data was already filed. The review was already running. GSK wasn't buying a bet on whether the science would work, Nuvalent had already de-risked that. It was buying a position in an outcome that was, by closing, close to locked in. That's a meaningfully different logic than the one usually applied to biotech M&A. Buying pre-Phase Ill is a science bet. Buying at this stage is a timing and distribution bet, the value is in being the company selling the drug the day it clears, not in the probability that it clears at all. Here we are waiting for data but big pharma due to patent cliff has other plans. ✌️🙏❤️‍🩹

  View on StockTwits ↗
• 
  Pat Nelis@2_logs_higher1d

  $AGEN $GSK, just get over it and acquire AGEN

  View on StockTwits ↗
• 
  Meril Knoxville@Meril_KnoxvilleBullish2d

  $BURL $BLK $GSK $HLN $NWSA sure

  View on StockTwits ↗
• 
  M@Mmssmm2d

  $QNCX FIRED Dirk Thye THIS SON OF A BITCCH DESTROYED SHAREHOLDERS VALUE ASK Lifesci to asked for acquisition by $PFE $AZN $GSK $MRK ….etc To acquire $QNCX for $100 a share And APOLOGIZE TO SHAREHOLDERS IMMEDIATELY NOW 😡

  View on StockTwits ↗
• 
  Michael Grant@RhoRevolution2d

  $GSK Hearing chatter about OZSC hiring a dedicated Chief Revenue Officer (CRO) with a massive network across commercial lighting and EV infrastructure. Turning tech into multi-million dollar contracts! 💰🚀

  View on StockTwits ↗
• 
  Open Outcrier@OpenOutcrier2d

  $GSK (+1.9% pre) GSK beats consensus forecast in second quarter https://ooc.bz/l/108838

  View on StockTwits ↗
• 
  Quantumup@Quantumup2d

  Guggenheim⬆️ $KYMR to $135 (was $125), reiterated Buy and said -- We think KYMR should be credited value if KT-579 shows healthy volunteer data in 2H26 that demonstrates safe >90% IRF5 degradation. $GSK $AUPH NVS RHHBY Here's what else Guggenheim had to say: https://x.com/Quantumup1/status/2082060908046479485?s=20

  View on StockTwits ↗
• 
  27R@27R3d

  $GSK Buckle up — earnings before the open tomorrow.

  View on StockTwits ↗
• 
  S@wyoming2020Bullish4d

  $GSK $MRK $LLY GSK moving Jemperli very quickly. Excellent trial results in rectal

  View on StockTwits ↗
• 
  S@wyoming2020BullishJul 23

  $GSK this has been such a sleeper that I didn't even look at this ticker in months. Big strides in oncology and big progress in better HIV treatment. This old dog has some new tricks it's showing off. Take a look

  View on StockTwits ↗
• 
  S@wyoming2020BullishJul 23

  $NUVL $GSK rectal approval next

  View on StockTwits ↗
• 
  S@wyoming2020Jul 23

  $GSK $SLS $PDSB $VKTX eyes on GSK with FDA approval for type of lunch cancer yesterday and a major rectal cancer drug on the brim. Just keeping boards aware

  View on StockTwits ↗
• 
  Tony M@SellasgpsCurativeBAT11BullishJul 23

  $SLS $ABBV $GSK $VRTX $MRK AbbVie paid a 49% premium for a drug with zero approvals. Here's why that's completely rational. Recently, AbbVie announced it would acquire Apogee Therapeutics for $10.9 billion, its largest buyout in over five years, according to Reuters. AbbVie is not alone. In 2026 alone: → GSK agreed to buy Nuvalent for $10.6 billion → Vertex is acquiring Crinetics Pharmaceuticals for $10 billion → Novartis bought Avidity Biosciences for $12 billion at a 46% premium This is the new pharma playbook. Internal R&D takes decades, but buying late-stage biotech assets is faster, more predictable, and increasingly the only way to protect revenue against patent cliffs. A ~49% premium sounds expensive until you compare it to the cost of having no pipeline when your patent runs out. SLS will keep on running towards its ultimate base upon upcoming Catalysts and Finally bidding war $240.00+

  View on StockTwits ↗
• 
  Tony M@SellasgpsCurativeBAT11BullishJul 20

  $SLS $GSK $NUVL GSK just paid $10.6 BILLION. That's what GSK is paying to acquire Nuvalent (NUVL). Big pharmaceuticals are in a buying frenzy with $380 Billion in patent expirations within next 2 years.

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.